相关实验视频

Updated: Jan 7, 2026

Antimicrobial Susceptibility Testing of Mycobacterium Tuberculosis Complex for First and Second Line Drugs by Broth Dilution in a Microtiter Plate Format

Antimicrobial Susceptibility Testing of Mycobacterium Tuberculosis Complex for First and Second Line Drugs by Broth Dilution in a Microtiter Plate Format

Published on: June 24, 2011

菌根菌对epetraborole的敏感性:它可以走多远?

S Singh¹, G D Boorgula¹, R-A Galvez²

¹Division of Infectious Diseases, Department of Medicine, University of Texas at Tyler School of Medicine, Tyler, TX, USA.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease

|December 18, 2025

概括

埃佩特拉博罗尔对抗耐药菌根菌具有前景,对抗Mycobacterium abscessus (MAB) 的最低最小抑制度 (MIC) 和对抗Mycobacterium avium complex (MAC) 的最佳微生物杀伤. 对于这些具有挑战性的肺部感染,建议进行进一步的药理动力学/药理动力学研究.

科学领域:

微生物学微生物学
传染性疾病传染性疾病
药理学药理学是指药理学的学科.

背景情况:

对抗耐药性Mycobacterium结核病 (MTB),Mycobacterium avium复合体 (MAC),Mycobacterium (MAB) 和Mycobacterium kansasii (MKN) 的新型化疗剂的需要.
一种新的leucyl-tRNA合成酶 (LeuRS) 抑制剂Epetraborole被评估为对抗这四种致病性菌根菌的有效性.

研究的目的:

评估epetraborole的体外活性与临床相关的MAB,MAC,MKN和MTB菌株.
为了确定最小抑制度 (MICs) 和度介于50%的最大效果 (EC50) 的epetraborole.

主要方法:

静态度-反应和最小抑制度 (MIC) 研究使用参考和临床菌株进行.
分析了数据,以计算MIC为50% (MIC50) 和90% (MIC90) 的分离物,以及EC50.0.

主要成果:

乙特拉波罗尔对MAB显示了最低的MIC50和MIC90值 (分别为0.25和0.5毫克/升).
观察到最强大的微生物杀伤是MAC感染.
在测试的菌根菌种中,MIC和EC50值各不相同,MAB显示最低值.

结论:

埃佩特拉博罗尔在体外对MAB,MAC,MKN和MTB表现出有希望的活性.
用MIC和EC50表示的药物的疗效对MAB是最有利的,而MAC显示出最好的杀死微生物.
需要进一步的药理动力学/药理动力学研究来探索epetraborole在治疗非结核性菌根和MTB肺部疾病方面的潜力.

更多相关视频

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments

Published on: October 25, 2024

Demonstrating a Multi-drug Resistant Mycobacterium tuberculosis Amplification Microarray

Demonstrating a Multi-drug Resistant Mycobacterium tuberculosis Amplification Microarray

Published on: April 25, 2014

相关概念视频

Pulmonary Tuberculosis V

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...